Peri-operative continuation of beta-blockers is recommended in patients currently receiving this medication.(Evidence: Level B，Recommendation: Class I)

In patients already on statins, it is recommended to continue statins during the peri-operative period.(Evidence: Level B，Recommendation: Class I)

In patients with stable HF, peri-operative continuation of RAAS inhibitors may be considered.(Evidence: Level C ，Recommendation: Class IIb)

In patients without HF, withholding RAAS inhibitors on the day of NCS should be considered to prevent peri-operative hypotension.(Evidence: Level B，Recommendation: Class IIa)

For patients on diuretics to treat hypertension,transient discontinuation of diuretics on the day of NCS should be considered.(Evidence: Level B，Recommendation: Class IIa)

It should be considered to interrupt SGLT-2 inhibitor therapy for at least 3 days before intermediate- and high-risk NCS.(Evidence: Level C，Recommendation: Class IIa)

It is recommended to delay elective NCS until 6 months after elective PCI and 12 months after an ACS.(Evidence: Level A ，Recommendation: Class I)

After elective PCI, it is recommended to delay time-sensitive NCS until a minimum of 1 month of DAPT treatment has been given.(Evidence: Level B，Recommendation: Class I)

In patients with a recent PCI scheduled for NCS, it is recommended that management of antiplatelet therapy is discussed between the surgeon, anaesthesiologist, and cardiologist.(Evidence: Level C，Recommendation: Class Ⅰ)

In high-risk patients with a recent PCI (e.g. STEMI patients or high-risk NSTE-ACS patients), a DAPT duration of at least 3 months should be considered before time-sensitive NCS.(Evidence: Level C，Recommendation: Class IIa)